Methenamine: a forgotten drug for preventing recurrent urinary tract infection in a multidrug resistance era - PubMed
Review
Methenamine: a forgotten drug for preventing recurrent urinary tract infection in a multidrug resistance era
Tze Shien Lo et al. Expert Rev Anti Infect Ther. 2014 May.
Abstract
In the era of multidrug resistance, it is critical to utilize antibiotics in an appropriate manner and to identify new treatments or revisit the use of 'forgotten' drugs. Because urinary tract infections (UTIs) are common, particularly in an increasing elderly population, the 'forgotten' drug, methenamine, may become important as a preventive therapy for recurrent UTIs. Methenamine, a urinary antibacterial agent, can be used as methenamine hippurate or methenamine mandelate preparations and is United States Food and Drug Administration-approved. This article discusses the place of preventive therapy for recurrent UTIs, chemistry, mechanism of action, pharmacology, clinical uses, dosage, adverse reactions and safety, and drug interactions of methenamine. Because of its unique antiseptic property, the authors suggest that methenamine should be considered when more commonly used antibiotics fail to suppress recurrent UTIs.
Similar articles
-
Gow JG. Gow JG. Practitioner. 1974 Jul;213(1273):97-101. Practitioner. 1974. PMID: 4280569 Clinical Trial. No abstract available.
-
Drug therapy reviews: methenamine mandelate and methenamine hippurate.
Gleckman R, Alvarez S, Joubert DW, Matthews SJ. Gleckman R, et al. Am J Hosp Pharm. 1979 Nov;36(11):1509-12. Am J Hosp Pharm. 1979. PMID: 391033 Review.
-
[Methenamine hippurate VUFB and mandelamine VUFB in the prevention of recurrent dysuria in women].
Horcicková M, Prát V, Hatala M, Nezádalová E, Milotová Z. Horcicková M, et al. Cas Lek Cesk. 1986 Jul 4;125(27):849-53. Cas Lek Cesk. 1986. PMID: 3731221 Czech. No abstract available.
-
Seppänen J, Sulkava T, Vaalasti T, Korhonen H, Räisänen S, Ylitalo P. Seppänen J, et al. Scand J Infect Dis. 1983;15(2):201-6. doi: 10.3109/inf.1983.15.issue-2.13. Scand J Infect Dis. 1983. PMID: 6603654 Clinical Trial.
-
Treatment of bacterial urinary tract infections: presence and future.
Wagenlehner FM, Naber KG. Wagenlehner FM, et al. Eur Urol. 2006 Feb;49(2):235-44. doi: 10.1016/j.eururo.2005.12.017. Epub 2006 Jan 18. Eur Urol. 2006. PMID: 16413668 Review.
Cited by
-
Bakhit M, Krzyzaniak N, Hilder J, Clark J, Scott AM, Mar CD. Bakhit M, et al. Br J Gen Pract. 2021 Jun 24;71(708):e528-e537. doi: 10.3399/BJGP.2020.0833. Print 2021 Jul. Br J Gen Pract. 2021. PMID: 34001538 Free PMC article.
-
Sardar A, Basireddy SR, Navaz A, Singh M, Kabra V. Sardar A, et al. J Clin Diagn Res. 2017 Feb;11(2):DC26-DC29. doi: 10.7860/JCDR/2017/23644.9440. Epub 2017 Feb 1. J Clin Diagn Res. 2017. PMID: 28384863 Free PMC article.
-
Gama CRB, Pombo MAG, Nunes CP, Gama GF, Mezitis SGE, Suchmacher Neto M, Guimarães OR, Geller M, Oliveira L, de Souza da Fonseca A, Sitnoveter A, Goldwasser G, Cunha KS, Darrigo Junior LG. Gama CRB, et al. Res Rep Urol. 2020 Dec 15;12:639-649. doi: 10.2147/RRU.S279060. eCollection 2020. Res Rep Urol. 2020. PMID: 33365282 Free PMC article.
-
Ngu EL, Tan CY, Lai NJ, Wong KH, Lim SH, Ming LC, Tan KO, Phang SM, Yow YY. Ngu EL, et al. Metabolites. 2022 Nov 20;12(11):1147. doi: 10.3390/metabo12111147. Metabolites. 2022. PMID: 36422287 Free PMC article.
-
Bishop AH. Bishop AH. Appl Environ Microbiol. 2017 Dec 1;83(24):e01722-17. doi: 10.1128/AEM.01722-17. Print 2017 Dec 15. Appl Environ Microbiol. 2017. PMID: 28970226 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical